InsidersTradesSigma
Tricida, Inc. Stock: price and management transactions · United States · SEC (Form 4)
Follow the Tricida, Inc. stock price and the full insider trade history of the company, a listed issuer based in United States. Shares trade on US US, under the supervision of SEC (Form 4). Operating in the Healthcare & Pharma sector, Tricida, Inc. has recorded 97 public disclosures. The latest transaction was filed on 25 November 2022 (Cession). Among the most active insiders: COUFAL SANDRA I. Every trade is openly available.
97
Insider Decl.
0
Thresholds
€19m
19 ops.
Buy Volume
€6m
47 ops.
Sell Volume
48Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 25 November 2022
Declarations97 total
131,879 shares@ US$0.2181.4% of flowCommon StockSEC:0001595585-22-000093:0
1,034,421 shares@ US$0.223.1% of flowCommon StockSEC:0000947871-22-001207:0
1,034,421 shares@ US$0.223.1% of flowCommon StockSEC:0000947871-22-001208:0
27,584 shares@ US$0.2318.6% of flowCommon StockSEC:0001595585-22-000091:0
2,113,948 shares@ US$0.616.6% of flowCommon StockSEC:0001209191-22-054671:0
40,400 shares@ US$11.982.5% of flowCommon StockSEC:0001209191-22-054201:0
Ideal exit: 15 Jul 2023 (T+270)
4,674 shares@ US$11.980.3% of flowCommon StockSEC:0001209191-22-053863:0
Ideal exit: 10 Jul 2023 (T+270)
95,366 shares@ US$12.0166.8% of flowCommon StockSEC:0001446472-22-000002:0
28,900 shares@ US$12.001.8% of flowCommon StockSEC:0001209191-22-053374:0
Ideal exit: 4 Jul 2023 (T+270)
223,100 shares@ US$11.8113.3% of flowCommon StockSEC:0001209191-22-052991:0
Ideal exit: 1 Jul 2023 (T+270)
14,995 shares@ US$10.679.2% of flowCommon StockSEC:0001744981-22-000004:0
168,187 shares@ US$9.928.6% of flowCommon StockSEC:0001209191-22-051925:0
Ideal exit: 26 Jun 2023 (T+270)
395,614 shares@ US$8.5617.8% of flowCommon StockSEC:0001209191-22-051501:0
Ideal exit: 23 Jun 2023 (T+270)
63,030 shares@ US$12.764.1% of flowCommon StockSEC:0001209191-22-048998:0
Ideal exit: 30 May 2023 (T+270)
50,000 shares@ US$12.203.1% of flowCommon StockSEC:0001209191-22-048246:0
Ideal exit: 27 May 2023 (T+270)
32,220 shares@ US$13.5023.9% of flowCommon StockSEC:0001744981-22-000003:0
18,900 shares@ US$9.210.9% of flowCommon StockSEC:0001209191-22-043953:0
Ideal exit: 25 Apr 2023 (T+270)
30,000 shares@ US$9.591.4% of flowCommon StockSEC:0001209191-22-043141:0
Ideal exit: 17 Apr 2023 (T+270)
100,000 shares@ US$9.024.5% of flowCommon StockSEC:0001209191-22-042695:0
Ideal exit: 14 Apr 2023 (T+270)
25,000 shares@ US$9.811.2% of flowCommon StockSEC:0001209191-22-042154:0
Ideal exit: 8 Apr 2023 (T+270)
55,700 shares@ US$9.652.6% of flowCommon StockSEC:0001209191-22-041196:0
Ideal exit: 28 Mar 2023 (T+270)
34,366 shares@ US$9.715.1% of flowCommon StockSEC:0001209191-22-039936:0
Ideal exit: 25 Mar 2023 (T+270)
142,900 shares@ US$10.9023.6% of flowCommon StockSEC:0001209191-22-039309:0
Ideal exit: 19 Mar 2023 (T+270)
5,951 shares@ US$9.690.9% of flowCommon StockSEC:0001209191-22-038479:0
Ideal exit: 13 Mar 2023 (T+270)
58,054 shares@ US$8.917.8% of flowCommon StockSEC:0001209191-22-036738:0
Ideal exit: 7 Mar 2023 (T+270)
25 of 97 declarations
About Tricida, Inc.
Tricida, Inc. is a U.S.-based biopharmaceutical company that was historically listed on the Nasdaq market in the United States, specifically on the Nasdaq Global Select Market under the ticker TCDA before its delisting trajectory associated with restructuring proceedings. The company was founded in 2013, incorporated in Delaware, and built its operating footprint in California, with principal offices in South San Francisco. Tricida’s business model centered on a single lead development asset, veverimer (also known as TRC101), an orally administered, non-absorbed polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD). In other words, Tricida was primarily a drug-development company rather than a diversified commercial pharmaceutical group, with its corporate value tied to the clinical, regulatory, and financing progress of one main candidate. That focused strategy gave the company a clear therapeutic thesis, but it also concentrated risk: the investment case depended heavily on regulatory acceptance, trial outcomes, and the company’s ability to secure funding long enough to reach commercialization. From a competitive standpoint, Tricida operated in a specialized renal/metabolic niche, competing indirectly with broader CKD-supportive therapies and other medical approaches, while lacking the product breadth, international scale, and commercial infrastructure of large-cap drug makers. Recent corporate history has been dominated by financial distress and restructuring. Tricida filed for Chapter 11 bankruptcy protection on January 11, 2023, and later disclosed plans to deregister its securities with the SEC and suspend reporting obligations. For investors, particularly those tracking SEC Form 4 insider activity, TCDA has been an example of a single-asset biotech with a high-risk, binary profile: promising scientific focus on one side, but substantial exposure on the other side to clinical uncertainty, regulatory setbacks, liquidity pressure, dilution, and eventual loss of exchange trading relevance. Given its U.S. market listing and Nasdaq history, any analysis of Tricida should be framed through the lens of the American public markets and the capital-intensive realities of late-stage biotech development.
